Antengene wins approval for Karyopharm’s selinexor as first and only XPO1 inhibitor in South Korea Aug. 3, 2021 By Doris Yu Antengene Corp. Ltd. has gained the first greenlight in Asia for the oral exportin 1 (XPO1) inhibitor selinexor, in-licensed from Karyopharm Therapeutics Inc., after South Korea’s Ministry of Food and Drug Safety gave the thumbs up for its NDA.Read More
